Journal profile · PARASITOLOGY-PHARMACOLOGY & PHARMACY
International Journal for Parasitology-Drugs and Drug Resistance
ISSN 2211-3207 · Elsevier BV · ENGLAND
International Journal for Parasitology-Drugs and Drug Resistance: CAS Zone 2 · Medicine (2025 upgraded edition); impact factor 3.49; fully open access; APC about USD 3,410; median 113 days to acceptance (101 articles, last 24 months); 56 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
International Journal for Parasitology-Drugs and Drug Resistance is published by Elsevier BV and is in Zone 2 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Helminth infection and control, Parasites and Host Interactions and Parasite Biology and Host Interactions, together about 36.3% of its articles. Its main subfields are Public Health, Environmental and Occupational Health. (generated from OpenAlex topic counts and CAS ranking data)
Sponsored by the Australian Society for ParasitologyThe International Journal for Parasitology – Drugs and Drug Resistance is one of a series of specialist, open access journals launched by the International Journal for Parasitology. It publishes the results of original research, as well as review articles, in the area of anti-parasite drug identification, development and evaluation, and parasite drug resistance. The journal also covers research into natural products as anti-parasitic agents, and bioactive parasite products. Studies can be aimed at unicellular or multicellular parasites of human or veterinary importance.A list showing the types of articles that are considered is included below. Original research includes the development of novel and innovative concepts and ideas, as well as experimental and observational science that raises new hypotheses. Because of its breadth of organism coverage, all contributions should include relevant information about the parasite of interest in order to be comprehensible to non-experts in the particular subject of the articles. The principal forms of publication are full-length articles which contain substantial results from a major program of research, or reviews on topical issues and strategically important subjects. The journal also accepts brief reports that have similar subject scope as the full-length article, but do not merit a full-length publication.In addition, the journal provides a medium for highlighting selected articles reporting highly significant original findings, as Editor's Choice Manuscripts. The journal encourages critical comment and debate on matters of current controversy in the area of parasite drug resistance and anti-parasite drugs via "Current Opinions".Types of articles considered:Compound library screening for inhibitors against enzymes or whole parasitesDrug target validation (chemical and/or genetic)Drug target identification (must include some inhibitor studies rather than characterisation of an enzyme, for example)Drug structure-activity relationship studiesMechanisms of drug action and resistanceReports of the development of drug resistance both in the field and laboratoryStudies on drug toxicity to the host (either on single host cells or whole organism)Reports on toxicity in the fieldComputational approaches to drug discovery or drug-target identificationDevelopment of assays directed at screening for inhibitorsDrug combination studiesNatural products as anti-parasitic agentsBioactive products produced by parasitesUse of live parasites as immunomodulatory agentsEpidemiological aspects of the emergence and spread of parasite drug resistanceHuman clinical trialsThe other specialist title in the series is International Journal for Parasitology: Parasites and Wildlife.
From the journal's Aims & Scope
Research area (LetPub): PARASITOLOGY-PHARMACOLOGY & PHARMACY
Editor-in-chief Sarah PrestonPublisher website
Editorial board by country: 1 in mainland China (about 2%); most named Australia 13, United Kingdom 11, United States 8, Switzerland 2, South Africa 2 (44 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Helminth infection and controlVeterinary13.7%
- Parasites and Host InteractionsImmunology and Microbiology12.4%
- Parasite Biology and Host InteractionsEnvironmental Science10.2%
- Research on Leishmaniasis StudiesMedicine9.2%
- Malaria Research and ControlMedicine8.2%
- Trypanosoma species research and implicationsMedicine7.5%
- Parasitic Infections and DiagnosticsImmunology and Microbiology6.2%
- Coccidia and coccidiosis researchAgricultural and Biological Sciences3.8%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Parasitology | Zone 1 |
| Minor | Pharmacology & Pharmacy | Zone 1 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Parasitology | Zone 2 |
| Minor | Pharmacology & Pharmacy | Zone 2 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Pharmacology & Pharmacy | Zone 1 |
| Minor | Parasitology | Zone 2 |
Top journal: noReview journal: no
Database indexing
SCIEScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 3.49LetPub ·
- Impact factor (publisher)
- 3.5Publisher website ·
- CiteScore 2026-06
- 5.8LetPub ·
- CiteScore (publisher)
- 5.8Publisher website ·
- SJR 2026-06
- 0.8LetPub ·
- SNIP 2026-06
- 1.42LetPub ·
- h-index
- 27LetPub ·
- h-index
- 69OpenAlex ·
- i10-index
- 450OpenAlex ·
- 2-year mean citedness
- 4.01OpenAlex ·
- Self-citation rate
- 8.6%LetPub ·
- Share of gold OA articles
- 100%LetPub ·
Volume
- Articles per year
- 55LetPub ·
Articles by year OpenAlex count · 672 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 41 | 41 | 12 |
| 2025 | 56 | 56 | 151 |
| 2024 | 56 | 56 | 450 |
| 2023 | 41 | 41 | 507 |
| 2022 | 37 | 37 | 683 |
| 2021 | 56 | 56 | 1,597 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
113 daysMedian, submission to acceptance · P25–P75 81 days – 139 days
- Acceptance to online
- median 2 days (101 articles)
- Submission to online
- median 116 days
- Sample
- 101 articles with submission and acceptance dates (115 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 23 weeksLetPub ·
- Submission to first decision
- 3 daysPublisher website ·
- First decision after review
- 37 daysPublisher website ·
- Submission to acceptance
- 118 daysPublisher website ·
- Acceptance to publication
- 2 daysPublisher website ·
- Submission to publication (journal-reported)
- about 18 weeksDOAJ ·
- Peer review
- Single anonymous peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessDOAJ
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | USD 3,410 | Yes | CC BY, CC BY-NC-ND | |
| OpenAlex | USD 2,700 / EUR 2,530 / GBP 2,160 / JPY 334,880 | — | — | |
| LetPub | USD 2,400 | Yes | — | |
| Publisher website | USD 3,550 | — | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
What to prepare7 items from the author guidelines
- Abstract
- ≤ 300 words
- Keywords
- ≥ 1
- Reference style
- Author–date
- First submission
- Free format: the journal's layout is not required
- Highlights
- Required
- Graphical abstract
- Required
- Not considered
- Drug target validation (chemical and/or genetic); Drug structure-activity relationship studies; Mechanisms of drug action and resistance; Reports on toxicity in the field
Article types accepted9
- commentThe journal encourages critical comment and debate on matters of current controversy in the area of parasite drug resistance and anti-parasite drugs via ‘Opinio…Length not stated
- editor's choice manuscriptsThe journal provides a medium for highlighting selected articles reporting highly significant original findings, as Editor's Choice Manuscripts.Length not stated
- full length articleThe principal form of publication is the full length article which contains substantial results from a major program of research.Length not stated
- opinionThe principal form of publication is the full length article which contains substantial results from a major program of research. We also publish ‘Short communi…Length not stated
- opinion paperThe journal encourages critical comment and debate on matters of current controversy in the area of parasite drug resistance and anti-parasite drugs via ‘Opinio…Length not stated
- reviewThe principal form of publication is the full length article which contains substantial results from a major program of research. We also publish ‘Short communi…Length not stated
- reviewsIn addition, the journal publishes focused Reviews of topical issues and strategically important subjects.Length not stated
- short communicationThe principal form of publication is the full length article which contains substantial results from a major program of research. We also publish ‘Short communi…Length not stated
- short communicationsWe also publish ‘Short communications’ that report substantial results.Length not stated
Policy excerpts from the journal's websiteAI use, Authorship, Conflicts of interest, License & copyright, Open access, Peer review, Preprints
- AI use Declaration of generative AI use
Authors must declare the use of generative AI tools in the manuscript preparation process upon submission of the paper.Generative AI and AI-assisted technologies (“AI tools”) have been rapidly adopted in research and scholarly publishing, offering significant benefits while requiring clear standards for responsible and transparent use.Authors preparing a manuscript for this journal may use AI tool…
Source ↗Publisher website ·- Authorship Group authorship
Group authorship refers to the attribution of an article to a defined and named group of authors whose members have contributed to the work. Examples include research consortia, clinical trial groups, collaborative networks, task forces or working groups, expert panels or consensus groups, and participatory research groups. Group authorship must be declared on the title page at submission. When av…
Source ↗Publisher website ·- Conflicts of interest Declaration of competing interests
All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence or bias their work. Examples of potential competing interests include:EmploymentConsultanciesStock ownershipHonorariaPaid expert testimonyPatent applications or registrationsGrants or any other fundingAffiliation with the journal as an Editor or Advisory Board …
Source ↗Publisher website ·- License & copyright License options
Authors will be offered open access user license options which will determine how you, and third parties, can reuse your open access article. We advise that you review these options and any funding body license requirements before selecting a license option.
Source ↗Publisher website ·- Open access Open access
We refer you to our open access information page to learn about open access options for this journal.
Source ↗Publisher website ·- Peer review Peer review
Single anonymized review process Model summary
This journal follows a single anonymized review process. Your submission will initially be assessed by our editors. If your submission is deemed suitable, it will typically be sent to be reviewed by a minimum of two reviewers for an independent expert assessment of the scientific quality. The decision as to whether your article is accepted or rejected for publication will be made by our editors.Re…
Source ↗Publisher website ·- Preprints Preprints
Preprint sharing allowed Model summary
Preprint sharingAuthors may share preprints in line with Elsevier's article sharing policy. Sharing preprints, such as on a preprint server, will not count as prior publication.We advise you to read our policy on multiple, redundant or concurrent publication.
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Elsevier BV
- Country or region
- ENGLAND
- Language
- English
- ISSN
- 2211-3207
- Official links
- Journal homepage ↗DOAJ
- Submission system ↗Publisher website
- Author guidelines ↗DOAJ
- Aims & Scope ↗DOAJ
- Special issues ↗Publisher website
- APC information ↗DOAJ
- Fee waivers ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗DOAJ
- Editorial board ↗DOAJ
- Plagiarism policy ↗DOAJ
FAQ
Frequently asked questions about International Journal for Parasitology-Drugs and Drug Resistance
What CAS zone is International Journal for Parasitology-Drugs and Drug Resistance in?
In the 2025 upgraded edition of the CAS Journal Ranking, International Journal for Parasitology-Drugs and Drug Resistance is in Zone 2 of Medicine, and in Zone 1 of the minor category Parasitology / Pharmacology & Pharmacy. In the 2026 Xinrui edition it is in Zone 2 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of International Journal for Parasitology-Drugs and Drug Resistance?
The latest impact factor listed by LetPub is 3.49; CiteScore 5.8, h-index 69.
How long does peer review take at International Journal for Parasitology-Drugs and Drug Resistance?
Based on the dates recorded on 101 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 113 days (interquartile range 81–139 days); authors report an average review time of about 23 weeks. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What are the manuscript requirements of International Journal for Parasitology-Drugs and Drug Resistance?
According to the journal's author guidelines: Abstract: ≤ 300 words; Keywords: ≥ 1; Reference style: Author–date; First submission: Free format: the journal's layout is not required; Highlights: Required; Graphical abstract: Required. A model extracted these from the author guidelines and each was checked against the text; check the latest version on the journal's website before submitting.
Where are the editorial board members of International Journal for Parasitology-Drugs and Drug Resistance based?
Of the 44 board members whose country the journal's board page names, 1 (about 2%) are in mainland China; the countries named most often are Australia (13), United Kingdom (11) and United States (8). Counted from the institutions listed on the board page; for reference only.
Which databases index International Journal for Parasitology-Drugs and Drug Resistance?
According to LetPub and DOAJ records, International Journal for Parasitology-Drugs and Drug Resistance is indexed in SCIE, Scopus and DOAJ.
Is International Journal for Parasitology-Drugs and Drug Resistance open access, and what is the APC?
International Journal for Parasitology-Drugs and Drug Resistance is a fully open-access journal. APC about USD 3,410.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex, DOAJ; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .